Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Borchmann

Showing results (221-230 of 252) with videos related to

Pageof 26
Sort By:
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Haematologica|May 4, 2023
B-cell receptor reactivity against <i>Rothia mucilaginosa</i> in nodular lymphocyte-predominant Hodgkin lymphomaLorenz Thurner, Natalie Fadle, Evi Regitz, et al.
The Lancet. Haematology|May 4, 2023
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumoursCristina Nanni, Carsten Kobe, Bettina Baeßler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 19, 2023
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyConrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, et al.
Leukemia|October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaMichael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Leukemia|July 1, 2026
Feasibility and safety of rapid glofitamab ramp-upCeline H Liem, Rebecca Wurm-Kuczera, David Böckle, et al.
Nature Medicine|October 23, 2023
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trialAndreas Mackensen, John B A G Haanen, Christian Koenecke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2024
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin LymphomaJan-Michel Heger, Laman Mammadova, Julia Mattlener, et al.
Pageof 26

Showing results (221-230 of 252) with videos related to

Sort By:
Pageof 26
The Lancet. Oncology|July 13, 2025
Fertility in patients with advanced-stage classic Hodgkin lymphoma treated with BrECADD versus eBEACOPP: a secondary analysis of the multicentre, randomised, parallel, open-label, phase 3 HD21 trialJustin Ferdinandus, Gundolf Schneider, Alden Moccia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2019
Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study GroupMichael Fuchs, Helen Goergen, Carsten Kobe, et al.
Haematologica|May 4, 2023
B-cell receptor reactivity against <i>Rothia mucilaginosa</i> in nodular lymphocyte-predominant Hodgkin lymphomaLorenz Thurner, Natalie Fadle, Evi Regitz, et al.
The Lancet. Haematology|May 4, 2023
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumoursCristina Nanni, Carsten Kobe, Bettina Baeßler, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 19, 2023
Multicenter development of a PET-based risk assessment tool for product-specific outcome prediction in large B-cell lymphoma patients undergoing CAR T-cell therapyConrad-Amadeus Voltin, Andrea Paccagnella, Michael Winkelmann, et al.
Leukemia|October 16, 2023
Follow-up of the GHSG HD16 trial of PET-guided treatment in early-stage favorable Hodgkin lymphomaMichael Fuchs, Anne Sophie Jacob, Helen Kaul, et al.
Lancet (London, England)|April 7, 2012
Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trialAndreas Engert, Heinz Haverkamp, Carsten Kobe, et al.
Leukemia|July 1, 2026
Feasibility and safety of rapid glofitamab ramp-upCeline H Liem, Rebecca Wurm-Kuczera, David Böckle, et al.
Nature Medicine|October 23, 2023
CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trialAndreas Mackensen, John B A G Haanen, Christian Koenecke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 30, 2024
Circulating Tumor DNA Sequencing for Biologic Classification and Individualized Risk Stratification in Patients With Hodgkin LymphomaJan-Michel Heger, Laman Mammadova, Julia Mattlener, et al.
Pageof 26